Release
📈 Stocks
Phanes Therapeutics Advances Peluntamig for Neuroendocrine Prostate Cancer
(just now)
Phanes Therapeutics accelerates the clinical development of Peluntamig (PT217), targeting the growing demand for specialized therapies in the treatment-resistant neuroendocrine prostate cancer…